Top Resources Top Resources
Web Results
  • 1.
    Alzheimer's Disease - Wikipedia
  • Hyperlinked article covering pathology, etiology, prevalence, diagnosis, prevention, nutrition, treatments, history, and more.
  • http://en.wikipedia.org/wiki/Alzheimers
Questions/Answers
alzheimers disease?
I am doing a report on Alzheimers Disease, and I need to know a few things 1) What percentage of the population has Alzheimers at different ages? 2) What happens inside the brain during the different stages of Alzheimers? 3) How long should a person with each stage of the disease expect to live? PLEASE INCLUDE YOUR SOURCES!!!! I NEED A BIBLIOGRAPY!!!!
Here are some partial answers: An Alzheimer's diagnosis cuts a person's remaining life expectancy in half. This is from a study of 521 people with newly diagnosed Alzheimer disease. They found that the median survival period was 4.2 years for men and 5.7 years for women, about half what a person of the same age who did not have the disease would be expected to live. It is the most common cause of dementia and affects 4.5 million Americans. However, according to the study, there has been no firm estimate of just how long an Alzheimer's patient has to live. Dr. Eric Larson and colleagues at the University of Washington followed 521 men and women over 60 who had been recently diagnosed with Alzheimer's disease. Those diagnosed in their 70s lived longer than those diagnosed at age 85 or older, said Larson, director of the Center for Health Studies at the Group Health Cooperative in Seattle and a former medical director of the University of Washington Medical Center. The study was funded by the National Institute on Aging and published in the Annals of Internal Medicine. In a paper published in the September 15, 2004, issue of Cerebral Cortex by Buckner and colleagues examined whether typical aging and Alzheimer's disease are on a continuum or distinct. The researchers used MRI to measure the volume of two regions of the brain previously linked with age-associated changes: the corpus callosum, and the medial temporal lobe. Comparing volume in young adults, older adults without dementia, and individuals with mild dementia of the Alzheimer type, they found clear differences between the effects of normal aging and Alzheimer's disease. The corpus callosum was smaller in older adults, regardless of whether they had dementia. In contrast, volume reductions in the hippocampus were markedly accelerated and larger in people with Alzheimer's disease.
Is it true that John McCainhas symptoms of Alzheimersdisease?
The man trembles and his speech becomes incoherent. He suffers from vertigo and forgets things, stumbles, has memory lapses and can't recall-or doesn't know-in which continent countries are. Are these all signs that he has the beginning stages of Alzheimers disease? Or does it simply mean that the man is a stupid, lame idiot?
Yes this is very much so. Beside Alzheimer's McCain is also senile and been brain damaged since Vietnam war. He belongs in the psychiatric ward instead of the White House.
What are biomedical engineersdoing at the moment foralzheimers disease?
is there any current technology for alzheimers disease? or a stroke
Alzheimers Disease One area of clinical research is focused on treating the underlying disease pathology. Reduction of amyloid beta levels is a common target of compounds under investigation. Immunotherapy or vaccination for the amyloid protein is one treatment modality under study. Unlike preventative vaccination, the putative therapy would be used to treat people already diagnosed. It is based upon the concept of training the immune system to recognise, attack, and reverse deposition of amyloid, thereby altering the course of the disease. An example of such a vaccine under investigation was ACC-001, although the trials were suspended in 2008. Another similar agent is bapineuzumab, an antibody designed as identical to the naturally induced anti-amyloid antibody. Other approaches are neuroprotective agents, such as AL-108, and metal-protein interaction attenuation agents, such as PBT2. A TNFα receptor fusion protein, etanercept has also showed encouraging results. Also, in 2008, two separate clinical trials showed positive results in modifying the course of disease in mild to moderate AD with methylthioninium chloride, a drug that inhibits tau aggregation and dimebon, an antihistamine.
knowledge base
* Indicates a required fieldAdd your knowledge or ask a question:
  • Display Name:(letters/numbers, no special characters)
  • Your knowledge or question:*
    (min: 100 characters, max: 2,000 characters)
  • Character count: 0
© 2009 ToseekA.com
Portions of this page powered by: yahoo!